The Adaptive Immunity and Homeostasis research group, headed by Jan Terje Andersen at the Department of Immunology, has developed a unique biomedical technology that can be used to create coagulation factors with a significantly longer duration of action than what is the case today. They have designed super albumin, which is a protein variant that can be coupled to protein-based drugs, and allow them to remain in the bloodstream for a considerable longer time.
Read original feature article about the technology from the University of Oslo home pages:
A new technology can improve the treatment of bleeding disorders
Article from Dagens Medisin (in Norwegian):
Har eksemplifisert ny norskutviklet biomedisinsk teknologi
Recent papers describing how coagulation factor VIIa and IX can be linked to super albumin to achieve favorable pharmacokinetics without affecting their without compromising the therapeutic properties:
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity
Lombardi S, Aaen KH, Nilsen J, Ferrarese M, Gjølberg TT, Bernardi F, Pinotti M, Andersen JT, Branchini A.
Br J Haematol. 2021 Jul;194(2):453-462. doi: 10.1111/bjh.17559. Epub 2021 Jun 9.
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics.
Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, Grevys A, Dalhus B, Wilson J, Høydahl LS, Christianson GJ, Roopenian DC, Schlothauer T, Michaelsen TE, Moe MC, Lombardi S, Pinotti M, Sandlie I, Branchini A, Andersen JT.
Sci Transl Med. 2020 Oct 14;12(565):eabb0580. doi: 10.1126/scitranslmed.abb0580.